logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
04/06/2025
Mingcheng Company MSCI Nordic Countries Index rose 0.6% to 358.57 points, with the Nordic healthcare sector leading the way. Novo Nordisk rose 4.7%, leading a group of constituent stocks.
Latest
3 m ago
AbbVie announced on June 4th that the National Medical Products Administration (NMPA) of China has approved Ruxolitinib (15mg once daily) for the treatment of adult patients with giant cell arteritis (GCA). This approval comes just over a month after its approval in the United States and European Union, making Ruxolitinib the first and only oral JAK inhibitor approved for the treatment of GCA in adult patients in China.
3 m ago
AbbVie: Ruxolitinib has been approved for a new indication in China for the treatment of adult giant cell arteritis.
4 m ago
Multiple headwinds are evident. Jefferies downgraded Rio Tinto (RIO.US) rating to "hold".
4 m ago
Outdoor camping concept stocks fluctuate and rise. Hals rises limit-up in the afternoon.
5 m ago
On June 4th, there were rumors that Elon Musk opposed Trump's tax reform plan because Musk was angry that Tesla, Starlink, SpaceX, and other projects did not receive preferential treatment. Musk later reposted that Trump's tax reform plan "not only makes all the government efficiency department's spending cuts efforts in vain". Musk had previously stated that this massive bill is "ridiculous and full of political manipulation". Musk said the bill will increase the budget deficit to $2.5 trillion, burdening American citizens with unbearable debt. White House press secretary Levi suggested that Elon Musk's criticism "will not change" President Trump's support for massive tax and spending legislation.
See all latestmore
logo
Contact US
qr
+852 - 60190728
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.